Adcendo Advances ADC Development with $135M Funding, Expands Global Cancer Therapy Options
Adcendo has successfully concluded a Series B funding round, raising $135 million to push forward its ADC programs, which are focused on addressing high unmet medical needs in cancer therapy[1][2]. The funding was led by TCGX, along with contributions from prominent investors like Novo Holdings, RA Capital Management, and Orbimed Advisors, among others[1][2]. This capital will be crucial in advancing their lead candidate, ADCE-T02, which targets solid tumors, and ADCE-D01, aimed at soft tissue sarcoma[1][2].
References
Explore Further
What are the potential challenges Adcendo might face in conducting clinical trials for ADCE-T02 and ADCE-D01?
How might Adcendo's antibody-drug conjugates differ in mechanism or effectiveness compared to existing cancer treatments?
What specific role do investors like Novo Holdings and RA Capital Management play in the development of Adcendo's ADCs?
How significant is the market opportunity for Adcendo's ADCs in addressing high unmet medical needs in cancer therapy globally?
What are the projected timelines for the commercialization of ADCE-T02 and ADCE-D01 following successful clinical trials?